2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FOXM1
  5. FOXM1 Inhibitor

FOXM1 Inhibitor

FOXM1 Inhibitors (16):

Cat. No. Product Name Effect Purity
  • HY-B0990
    Thiostrepton
    		Inhibitor 99.80%
    Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation.
  • HY-112721
    FDI-6
    		Inhibitor 99.60%
    FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
  • HY-19979
    RCM-1
    		Inhibitor 98.56%
    RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research.
  • HY-158420
    STL001
    		Inhibitor 99.81%
    STL001 is potent and selective FOXM1 inhibitor. STL001 induces the translocation of nuclear FOXM1 to the cytoplasm and promotes its autophagic degradation. STL001 sensitizes human cancers to a broad-spectrum of cancer therapies.
  • HY-148530
    YX-2-107
    		Inhibitor 98.60%
    YX-2-107 is a PROTAC (IC50= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph+ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • HY-181076
    FOXM1-IN-3
    		Inhibitor
    FOXM1-IN-3 is a potent FOXM1 inhibitor. FOXM1-IN-3 downregulates FOXM1 expression at protein and mRNA levels, suppressing downstream effectors CCNB1 and CDC25. FOXM1-IN-3 induces G2/M cell cycle arrest and apoptosis in colorectal cancer cells. FOXM1-IN-3 inhibits colony formation and cell migration in colorectal cancer cells. FOXM1-IN-3 targets the cancer stem cell phenotype in colorectal cancer cells, reducing cancer stem cell marker expression. FOXM1-IN-3 reduces tumor growth in a zebrafish xenograft model. FOXM1-IN-3 can be used for the research of colorectal cancer.
  • HY-182285
    5-HT7 modulator-1
    		Inhibitor
    5-HT7 modulator-1 is a selective 5-HT7 receptor antagonist with a Ki of 92 nM. 5-HT7 modulator-1 blocks 5-HT7 receptor signaling to reduce FOXM1, phosphorylated FOXM1, cyclin B1, and cdc25B levels. 5-HT7 modulator-1 acts as an antiproliferative, clonogenic inhibitor, and cell cycle inhibitor that induces G2/M arrest, reduces G0/G1 population. 5-HT7 modulator-1 can be used for the research of triple-negative breast cancer.
  • HY-151986
    FOXM1-IN-1
    		Inhibitor 99.86%
    FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC50 value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein.
  • HY-P1687
    Siomycin A
    		Inhibitor
    Siomycin A is a thiopeptide antibiotic and is a Forkhead box M1(FOXM1) selective inhibitor without affecting other members of the Forkhead box family. Siomycin A has anti-tumor and promotes apoptosis.
  • HY-170552
    KC12
    		Inhibitor
    KC12 is an inhibitor for FOXM1 transcription factor. KC12 exhibits cytotoxicity in cancer cell MDA-MB-231 with an IC50 of 6.13 µM.
  • HY-178462
    Hsp70/FoxM1-IN-1
    		Inhibitor
    Hsp70/FoxM1-IN-1 (Compound 7d) is a potent heat shock protein 70 (Hsp70) and Forkhead box M1 (FoxM1) dual inhibitor. Hsp70/FoxM1-IN-1 demonstrates significant antiproliferative and pro-apoptotic effects in multiple solid tumor models (e.g., breast, colorectal cancer), particularly for tumors co-overexpressing Hsp70/FoxM1.
  • HY-150038
    NOSH-aspirin
    		Inhibitor
    NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease.
  • HY-161617
    LASSBio-2052
    		Inhibitor
    LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells.
  • HY-156609
    FOXM1-IN-2
    		Inhibitor
    FOXM1-IN-2 is a FOXM1 inhibitor, with antineoplastic activity.
  • HY-112509
    STL427944
    		Inhibitor
    STL427944 is a potent and selective FOXM1 inhibitor. STL427944 has the potential for the research of overcoming tumor chemoresistance.
  • HY-N19821
    Gangaleoidin
    		Inhibitor
    Gangaleoidin is a FOXM1 inhibitor with an IC50 of 2.8 μM. Gangaleoidin inhibits interaction between FOXM1’s DNA-binding domain and target DNA sequence, downregulates FOXM1 and downstream target gene CCNB1 at the transcriptional level. Gangaleoidin suppresses proliferation of FOXM1-overexpressing breast cancer cells. Gangaleoidin can be used for the research of breast cancer.